A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A phase 2 trial of Patritumab deruxtecan in melanoma and cervical cancer, run by Daiichi Sankyo, now recruiting.
Overview
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06172478 by Daiichi Sankyo, with 740 participants planned, started 2024-02-26 and due to reach its primary completion in 2027-09-01. Interventions recorded: HER3-DXd. Conditions listed: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialHERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Shares Patritumab deruxtecan, Daiichi Sankyo, Non-small-cell lung cancer.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Cervical cancer, Prostate cancer, Non-small-cell lung cancer.
- TrialStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Shares Patritumab deruxtecan, Daiichi Sankyo.
- TrialA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Shares Patritumab deruxtecan, Daiichi Sankyo.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer, Melanoma, Prostate cancer.
- TrialStudy of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Shares Daiichi Sankyo, Endometrial cancer.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer.